-

09:16:37 PM

IFRX Stock News

IFRX - InflaRx N.V.

11/09/22 7:40 AM

Nasdaq : IFRX

InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904

Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiated Study designed as single ascending dose to determine safety, tolerability and pharmacokinetics in healthy volunteers Future development in complement-mediated chronic diseases

RHEA-AI

neutral

11/09/22 7:30 AM

Nasdaq : IFRX

InflaRx Reports Third Quarter 2022 Financial & Operating Results

Vilobelimab earns Orphan Drug and Fast Track designation for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients - Emergency Use Authorization (EUA) submitted to U.S. Food and Drug Administration (FDA) PANAMO Phase III study results in severe COVID-19 published in

RHEA-AI

neutral

09/29/22 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patients EUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The Lancet Respiratory Medicine Request for EUA follows encouraging interactions with FDA in

RHEA-AI

positive

09/09/22 7:30 AM

Nasdaq : IFRX

conferences

InflaRx to Present at Upcoming Scientific and Investor Conferences

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several conferences. H.C. Wainwright 24 th Annual Global

RHEA-AI

neutral

09/08/22 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine

The Lancet Respiratory Medicine, a peer-reviewed journal, published the results of the PANAMO trial, one of the largest, global, 1:1 randomized, placebo-controlled Phase III studies conducted in invasively mechanically ventilated, critically ill COVID-19 patients In-depth statistical analysis

RHEA-AI

neutral

08/05/22 7:00 AM

Nasdaq : IFRX

InflaRx Reports Second Quarter 2022 Financial & Operating Results

Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDA Plans to submit EUA with the FDA for vilobelimab in critically ill COVID-19 patients announced Grant income of €14.4 million realized during the second quarter Cash, cash equivalents and

RHEA-AI

neutral

07/26/22 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement

RHEA-AI

neutral

07/06/22 7:30 AM

Nasdaq : IFRX

InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage

RHEA-AI

very positive

06/29/22 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA Productive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program design Type B meeting scheduled with FDA; dialogue ongoing with EMA for development in severe

RHEA-AI

positive

05/17/22 7:30 AM

Nasdaq : IFRX

conferences

InflaRx to Present at the H.C. Wainwright Global Investment Conference

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H.C. Wainwright

RHEA-AI

neutral

1 2 3 4 5 6 Next

IFRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.inflarx.de
Security nameInflaRx N.V.
Issue typecs
SectorManufacturing
Sic code2834
Employees49
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressWinzerlaer Str. 2
StateThueringen
CityJena
Zip07745
CountryGermany
Phone493641508180

About InflaRx N.V.

InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.